JOP20170169A1 - مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو - Google Patents
مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسوInfo
- Publication number
- JOP20170169A1 JOP20170169A1 JOP/2017/0169A JOP20170169A JOP20170169A1 JO P20170169 A1 JOP20170169 A1 JO P20170169A1 JO P20170169 A JOP20170169 A JO P20170169A JO P20170169 A1 JOP20170169 A1 JO P20170169A1
- Authority
- JO
- Jordan
- Prior art keywords
- compounds useful
- fused tricyclic
- pyridazinone compounds
- treat
- orthomyxovirus infections
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Abstract
يعمل الاختراع على إعداد مركبات لها الصيغة (I): (أ) كما هو مبين هنا، علاوة على ذلك يتعلق الاختراع بتركيبات صيدلانية تحتوي على هذه المركبات، وطرق لاستخدام هذه المركبات وتركيبات صيدلانية لعلاج بعض الاضطرابات الفيروسية، بما في ذلك الأنفلونزا.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662380712P | 2016-08-29 | 2016-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20170169A1 true JOP20170169A1 (ar) | 2019-01-30 |
Family
ID=59923494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2017/0169A JOP20170169A1 (ar) | 2016-08-29 | 2016-08-29 | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
Country Status (15)
Country | Link |
---|---|
US (3) | US10160764B2 (ar) |
EP (3) | EP3848372B1 (ar) |
JP (2) | JP7221861B2 (ar) |
CN (2) | CN109863151B (ar) |
AR (1) | AR109438A1 (ar) |
CA (1) | CA3035302A1 (ar) |
ES (1) | ES2859510T3 (ar) |
JO (1) | JOP20170169A1 (ar) |
MX (1) | MX2019002438A (ar) |
PL (1) | PL3504214T3 (ar) |
PT (2) | PT3504214T (ar) |
SI (1) | SI3504214T1 (ar) |
TW (2) | TW202342482A (ar) |
UY (1) | UY37378A (ar) |
WO (1) | WO2018042303A1 (ar) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9328119B2 (en) * | 2013-09-12 | 2016-05-03 | Alios Biopharma, Inc. | AZA-pyridone compounds and uses thereof |
SG11201804348SA (en) | 2015-12-15 | 2018-06-28 | Shionogi & Co | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug |
ES2881776T3 (es) | 2016-03-08 | 2021-11-30 | Novartis Ag | Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus |
CA3033180C (en) | 2016-08-10 | 2022-05-31 | Shionogi & Co., Ltd. | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
JOP20170169A1 (ar) * | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
JP7352297B2 (ja) | 2018-01-17 | 2023-09-28 | 江西彩石医薬科技有限公司 | ピリドン誘導体と、その組成物、並びにそれらが抗ウイルス薬物としての応用 |
KR102521320B1 (ko) * | 2018-02-28 | 2023-04-13 | 노파르티스 아게 | 인플루엔자의 치료를 위한 오르토믹소바이러스 복제의 억제제로서의 10-(디(페닐)메틸)-4-히드록시-8,9,9a,10-테트라히드로-7h-피롤로[1',2':4,5]피라지노[1,2-b]피리다진-3,5-디온 유도체 및 관련 화합물 |
CN108440564B (zh) * | 2018-04-11 | 2019-08-06 | 安帝康(无锡)生物科技有限公司 | 被取代的多环氨基甲酰基吡啶酮衍生物及其前药 |
EP3864020A1 (en) * | 2018-10-10 | 2021-08-18 | Janssen BioPharma, Inc. | Macrocyclic flu endonuclease inhibitors |
WO2021129602A1 (zh) * | 2019-12-23 | 2021-07-01 | 石家庄迪斯凯威医药科技有限公司 | 取代的多环化合物及其药物组合物和用途 |
WO2022105669A1 (zh) * | 2020-11-17 | 2022-05-27 | 南京明德新药研发有限公司 | 含Se大环类化合物 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8501542D0 (en) | 1985-01-22 | 1985-02-20 | Erba Farmitalia | 4 5 6 7-tetrahydro-imidazo(4 5-clpyridine derivatives |
AUPM354694A0 (en) | 1994-01-27 | 1994-02-17 | Biota Scientific Management Pty Ltd | Chemical compounds |
EP1422218B1 (en) | 2001-08-10 | 2012-03-21 | Shionogi & Co., Ltd. | Antiviral agent |
CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
EP1725554A1 (en) | 2004-03-09 | 2006-11-29 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Hiv integrase inhibitors |
FR2901795A1 (fr) | 2006-05-30 | 2007-12-07 | Fourtillan Snc | Derives de pyrimidino[1',6'-1,2]pyrido[3,4-b]indoles et leur utilisation en therapeutique |
HUE031802T2 (en) | 2008-10-31 | 2017-08-28 | Shionogi & Co | Catechol Cephalosporin |
JP5697163B2 (ja) | 2009-03-26 | 2015-04-08 | 塩野義製薬株式会社 | 置換された3−ヒドロキシ−4−ピリドン誘導体 |
TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
HUE038837T2 (hu) | 2009-06-15 | 2018-11-28 | Shionogi & Co | Helyettesített policiklusos karbamoilpiridon-származék |
AU2010336509A1 (en) | 2009-12-23 | 2012-07-19 | Elan Pharmaceuticals, Inc | Pteridinones as inhibitors of polo-like kinase |
US8541407B2 (en) | 2010-03-31 | 2013-09-24 | Arqule, Inc. | Substituted benzo-pyrido-triazolo-diazepine compounds |
US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
KR101773226B1 (ko) * | 2010-09-24 | 2017-09-12 | 시오노기세야쿠 가부시키가이샤 | 치환된 다환성 카르바모일 피리돈 유도체의 프로드러그 |
US9328075B2 (en) | 2011-05-05 | 2016-05-03 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for treating influenza |
WO2013054862A1 (ja) * | 2011-10-12 | 2013-04-18 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有する多環性ピリドン誘導体 |
ES2604766T3 (es) | 2012-09-20 | 2017-03-09 | Celltrion, Inc. | Derivado de dolastatina-10, procedimiento de producción del mismo y composición de fármaco anticanceroso que contiene el mismo |
SG11201503946UA (en) | 2013-01-08 | 2015-09-29 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
UA123854C2 (uk) | 2013-08-21 | 2021-06-16 | Аліос Біофарма, Інк. | Противірусні сполуки |
WO2015038665A1 (en) | 2013-09-11 | 2015-03-19 | University Of Southern California | A composition of stem cells having highly expressed fas ligand |
US9328119B2 (en) * | 2013-09-12 | 2016-05-03 | Alios Biopharma, Inc. | AZA-pyridone compounds and uses thereof |
CN105722831B (zh) | 2013-09-12 | 2019-08-06 | 艾丽奥斯生物制药有限公司 | 哒嗪酮化合物及其用途 |
CN107074880A (zh) | 2014-07-07 | 2017-08-18 | 萨维拉制药有限公司 | 二氢吡啶并吡嗪‑1,8‑二酮和它们在治疗、改善或预防病毒疾病中的用途 |
EP3268368A4 (en) | 2015-03-11 | 2018-11-14 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
ES2881776T3 (es) | 2016-03-08 | 2021-11-30 | Novartis Ag | Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus |
US10183945B2 (en) | 2016-03-10 | 2019-01-22 | Alios Biopharma, Inc. | Method of preparing AZA-pyridone compounds |
BR112018077136A2 (pt) | 2016-07-01 | 2019-04-30 | G1 Therapeutics, Inc. | composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis. |
WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
CA3033180C (en) | 2016-08-10 | 2022-05-31 | Shionogi & Co., Ltd. | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
JP2019059697A (ja) * | 2017-09-28 | 2019-04-18 | 塩野義製薬株式会社 | 置換された多環性ピリダジン誘導体およびそのプロドラッグ |
JP7352297B2 (ja) | 2018-01-17 | 2023-09-28 | 江西彩石医薬科技有限公司 | ピリドン誘導体と、その組成物、並びにそれらが抗ウイルス薬物としての応用 |
CN110041327B (zh) | 2018-01-17 | 2022-01-21 | 江西彩石医药科技有限公司 | 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用 |
AU2019228916A1 (en) | 2018-02-28 | 2020-07-02 | Japan Tobacco Inc. | Saturated ring-condensed dihydropyrimidinone or dihydrotriazinone compound, and pharmaceutical use thereof |
KR102521320B1 (ko) | 2018-02-28 | 2023-04-13 | 노파르티스 아게 | 인플루엔자의 치료를 위한 오르토믹소바이러스 복제의 억제제로서의 10-(디(페닐)메틸)-4-히드록시-8,9,9a,10-테트라히드로-7h-피롤로[1',2':4,5]피라지노[1,2-b]피리다진-3,5-디온 유도체 및 관련 화합물 |
CN111741947A (zh) | 2018-02-28 | 2020-10-02 | 日本烟草产业株式会社 | 4-甲基二氢嘧啶酮化合物及其药物用途 |
WO2019166432A1 (en) | 2018-02-28 | 2019-09-06 | F. Hoffmann-La Roche Ag | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer |
-
2016
- 2016-08-29 JO JOP/2017/0169A patent/JOP20170169A1/ar unknown
-
2017
- 2017-08-25 EP EP20210329.7A patent/EP3848372B1/en active Active
- 2017-08-25 US US15/686,652 patent/US10160764B2/en active Active
- 2017-08-25 US US16/328,616 patent/US11098051B2/en active Active
- 2017-08-25 CA CA3035302A patent/CA3035302A1/en active Pending
- 2017-08-25 MX MX2019002438A patent/MX2019002438A/es unknown
- 2017-08-25 PL PL17771587T patent/PL3504214T3/pl unknown
- 2017-08-25 JP JP2019511749A patent/JP7221861B2/ja active Active
- 2017-08-25 PT PT177715877T patent/PT3504214T/pt unknown
- 2017-08-25 EP EP23217305.4A patent/EP4356969A2/en active Pending
- 2017-08-25 WO PCT/IB2017/055137 patent/WO2018042303A1/en unknown
- 2017-08-25 SI SI201730650T patent/SI3504214T1/sl unknown
- 2017-08-25 CN CN201780065653.XA patent/CN109863151B/zh active Active
- 2017-08-25 CN CN202110956692.7A patent/CN113683614A/zh active Pending
- 2017-08-25 EP EP17771587.7A patent/EP3504214B1/en active Active
- 2017-08-25 PT PT202103297T patent/PT3848372T/pt unknown
- 2017-08-25 ES ES17771587T patent/ES2859510T3/es active Active
- 2017-08-28 TW TW112101158A patent/TW202342482A/zh unknown
- 2017-08-28 UY UY0001037378A patent/UY37378A/es unknown
- 2017-08-28 TW TW106129086A patent/TWI803467B/zh active
- 2017-08-29 AR ARP170102385A patent/AR109438A1/es unknown
-
2021
- 2021-07-13 US US17/374,237 patent/US11912715B2/en active Active
-
2022
- 2022-11-22 JP JP2022186394A patent/JP2023027102A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200123167A1 (en) | 2020-04-23 |
CA3035302A1 (en) | 2018-03-08 |
US10160764B2 (en) | 2018-12-25 |
MX2019002438A (es) | 2019-07-08 |
TWI803467B (zh) | 2023-06-01 |
EP3504214B1 (en) | 2020-12-02 |
JP2019532033A (ja) | 2019-11-07 |
PT3504214T (pt) | 2021-03-04 |
EP3848372B1 (en) | 2023-12-20 |
PT3848372T (pt) | 2024-03-22 |
TW202342482A (zh) | 2023-11-01 |
TW201811800A (zh) | 2018-04-01 |
EP4356969A2 (en) | 2024-04-24 |
ES2859510T3 (es) | 2021-10-04 |
CN109863151B (zh) | 2021-09-10 |
CN113683614A (zh) | 2021-11-23 |
WO2018042303A1 (en) | 2018-03-08 |
CN109863151A (zh) | 2019-06-07 |
EP3504214A1 (en) | 2019-07-03 |
UY37378A (es) | 2018-03-23 |
US20180057501A1 (en) | 2018-03-01 |
AR109438A1 (es) | 2018-11-28 |
JP2023027102A (ja) | 2023-03-01 |
US20220041610A1 (en) | 2022-02-10 |
SI3504214T1 (sl) | 2021-04-30 |
EP3848372A1 (en) | 2021-07-14 |
US11912715B2 (en) | 2024-02-27 |
JP7221861B2 (ja) | 2023-02-14 |
US11098051B2 (en) | 2021-08-24 |
PL3504214T3 (pl) | 2021-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019002438A (es) | Compuestos triciclicos fusionados de piridazinona utiles para tratar infecciones de orthomyxovirus. | |
CL2019002204A1 (es) | Compuestos inhibidores del vih. | |
PH12018502026A1 (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
PH12018502077A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
PH12019502201A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
CL2020000886A1 (es) | Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih. | |
PH12019502577A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
CR20200152A (es) | DERIVADOS DE INDOL MONO-O-DI-SUSTITUIDOS COMO INHIBIDORES DE LA REPLICACIÓN VIRAL DEL DENGUE (Divisonal 2017-0490) | |
PH12018502015A1 (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
EA201690372A1 (ru) | Азапиридоновые соединения и их применение | |
MX2018011788A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
MX2022000453A (es) | Compuestos útiles para tratar infecciones por virus de influenza. | |
MY197698A (en) | Oxysterols and methods of use thereof | |
PH12018500576A1 (en) | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | |
PH12019502095A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
EA201790700A1 (ru) | Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге | |
PH12019502559A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
PH12019502363A1 (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
MX2018002446A (es) | Compuestos heterociclicos fusionados como moduladores s1p. | |
PH12016501613A1 (en) | Pyrazines modulators of gpr6 | |
WO2015198263A3 (en) | Novel betulinic proline substituted derivatives as hiv inhibitors | |
PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
MX2016009250A (es) | Nuevos imidazoles para el tratamiento y profilaxis de la infeccion por virus sincicial respiratorio. | |
MX2017005669A (es) | Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos. |